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Long-term cancer survivors risk development of second primary cancers (SPC). Vigilant follow-up may be required. We report
outcomes of 92 patients who underwent chemoradiation for unresectable stage III non-small-cell lung cancer, with a median follow-
up of 8.9 years. The incidence of SPC was 2.4 per 100 patient-years (95% confidence interval: 1.0–4.9).
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Second primary cancer (SPC) and secondary leukaemia have been
recognised in survivors of non-metastatic non-small-cell lung
cancer (NSCLC) (Duchateau and Stokkel, 2005). In one study in
which, 547 patients were treated with chemoradiation (CRT) using
a variety of chemotherapeutic regimens, radiation (RT) doses, and
schedules (Kawaguchi et al, 2006). Sixty-two patients were disease
free more than 3 years, but nine of them developed SPC with an
incidence estimated at 2.9 per 100 patient-years. Furthermore, the
causes of death in long-term survivors of advanced NSCLC have
not been fully described. More data are required to understand the
risk of SPC and to establish guidelines for follow-up after
combined modality treatment.
We previously reported the 2- or 3-year survival outcomes of
two concurrent CRT regimens in surgically unresectable stage III
NSCLC (Segawa et al, 2000; Kiura et al, 2003). Here we report long-
term results on cause of death and analysis of SPC in these two
trials with a minimum follow-up period of 5 years.
PATIENTS AND METHODS
Patients
Between January 1994 and December 1999, two phase II
concurrent CRT studies for locally advanced unresectable stage
IIIA and IIIB NSCLC in a total of 92 patients were conducted.
Briefly, patients had histologically or cytologically confirmed
NSCLC, previously untreated disease, measurable lesions, age
p75 years, and no history of malignancy within 5 years of
enrollment. Any patients who had previously undergone chemo-
therapy or radiotherapy were excluded. Institutional review boards
approved study protocols, and patients provided written informed
consent. Treatment in one study consisted of three cycles of 5-
fluorouracil (500mg/m
2, days 1–5) and cisplatin (FP-RT) (20mg/
m
2, days 1–5), every 4 weeks, and concurrent hyperfractionated
RT (1.25Gy twice daily, total dose: 62.5–70Gy) (FP-RT). In the
second study, treatment consisted of combination docetaxel
40mg/m
2 and cisplatin (DP-RT) 40mg/m
2, days 1, 8, 29, and 36
with concurrent RT (2Gy daily, total 60Gy) (DP-RT). For the first
2 years following therapy, patients were monitored monthly with
chest radiography and every 6 months with computed tomography
(CT) (chest and abdomen) and magnetic resonance imaging
(brain). After 2 years, chest radiography was performed annually
whereas annual brain MRI and semi-annual CT continued.
SPC in the lung was defined according to the methods of
Martini and Melamed (1975). Patients’ status was described
according to Eastern Cooperative Oncology Group performance
status (PS).
Statistical analysis
Statistical analyses were performed using the SPSS program
version 11.0J (SPSS Inc., Chicago, IL, USA). Survival time was
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sdefined as the period from CRT treatment initiation to last follow-
up evaluation or death. SPC rate was calculated as the ratio of SPC
cases over 100 patient-years of follow-up (Thomas and Rubinstein,
1993; Jeremic et al, 2001).
The interval of initial NSCLC to SPC was measured from the
initiation of CRT to SPC diagnosis, where the date of first clinical
evidence of histologically or cytologically confirmed SPC was
used. Survival rates and cumulative risks of developing SPC
were calculated using Kaplan and Meier method and differences
in survival distribution between two categorised groups were
assessed using a log-rank test. P-values less than 0.05 in two-tailed
analyses were considered significant. Analyses of these data are
based on information available as of 1 October 2005. Data for
patients still alive at last follow-up or dead without developing SPC
were censored when calculating the cumulative risks.
RESULTS
In the first study, 50 patients were treated with FP-RT and in the
second study 42 patients were treated with DP-RT. Among these 92
patients were 81 men and 11 women. At treatment initiation, 21
patients had stage IIIA and 71 patients had stage IIIB disease. The
median age for all patients was 65 years (range; 29–75 years).
Performance status was 0 (n¼35), one (n¼54) and two (n¼3).
With a median follow-up time of 8.9 years (range, 5.2–11.4 years),
the observed 5-year survival rate was 30%, with 28 of 92 patients
surviving more than 5 years. Median survival time was 2.0 years
(95% confidence interval (CI): 1.6–2.5 years) (Figure 1). In the FP-
RT study the 5-year survival rate was 30% and in the DP-RT study
it was 31%. The median survival times were 1.6 years (95% CI:
0.91–2.25 years) and 2.1 years (95% CI: 0.82–2.5 years),
respectively.
Among the 92 patients, two did not complete the originally
planned treatment. One had a treatment-related death and another
developed cerebral infarction; they were therefore not included in
this analysis. Of the remaining 90 patients, 61 (68%) eventually
developed disease progression. The most common site of initial
failure was within the site of original disease (local progression
only, n¼28; local plus distant progression, n¼8; distant
progression only n¼24; unspecified, n¼1). Brain metastases
were observed in eight patients, and for six it was the only site of
relapse. Among the 28 patients who survived more than 5 years,
four died owing to progression of primary NSCLC, three died
owing to SPC, two were lost to follow-up, and 19 were alive. Four
of the 19 long-term survivors developed SPC (two NSCLC, one
small-cell lung cancer, and one oesophageal cancer). Thus, from 90
patients initially included in the two studies a total of seven (7.8%)
developed SPC (two NSCLC, one small-cell lung cancer, two
oesophageal cancer, and two biliary tract cancer) (Table 1). No
patients developed leukaemia or myelodysplastic syndrome.
The two patients with second NSCLC (both stage IA) underwent
surgery, whereas the patient with small-cell lung cancer (limited
disease) received chemotherapy. All were alive at the time of data
cutoff. In the two patients with oesophageal cancer, one was alive
and the other had died at the time of data cutoff. The former
had cancer detected by routine endoscopy, in the absence of
symptoms; the latter was diagnosed with advanced disease after
developing dysphagia. The patient with gall bladder cancer
reported abdominal pain, but despite surgery with curative intent,
died of SPC. The patient with bile duct cancer presented with
jaundice, received palliative chemotherapy, and died of SPC. All
patients who developed SPC had a history of smoking, but only
one continued after the diagnosis of primary NSCLC was made.
Only one SPC arose in the RT treatment of initial NSCLC.
The observed incidence rate of SPC was 2.4 per 100 patient-years
(95% CI: 1.0–4.9). Cumulative incidence was 2.7% (standard error
s.e. 2.6%) at 3 years, 5.8 % (s.e. 4.0%) at 5 years, 10.0% (s.e. 5.6%)
at 8 years, 41.8% (s.e. 15.3%) at 9 years, and 60.8% (s.e. 18.9%) at
10 years (Figure 2). The median time from the beginning of CRT
to the diagnosis of SPC was 9.6 years (95% CI: 8.1–11.1 years). All
patients with SPC showed no progressive disease of the primary
NSCLC.
DISCUSSION
The analysis of data after a median 8.9 years demonstrates that for
patients treated with CRT for unresectable NSCLC in our previous
studies, the 5-year-survival rate was 30%. In the patients who
underwent rigorous follow-up detection of SPC was assured. Three
primary lung cancers were detected during routine follow-up and
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Figure 1 Overall survival curve from the initiation of concurrent CRT.
Table 1 Characteristics of seven patients with SPC following chemoradiation
Type of SPC
First to second
cancer (years)
Smoking
(pack-year) Chemo RT field First symptom
Treatment of
SPC
Survival after SPC
(years)
Gall bladder 2.5 100 DP Outside Abdominal pain Curative operation 1.2 (died of SPC)
Oesophagus 4.1 30 FP Outside None Curative chemo RT 7.2 (alive)
Lung (adeno) 5.9 30 DP Outside None Curative operation 1.6 (alive)
Oesophagus 8.3 50 FP Inside Dysphagia Palliation 0.35 (died of SPC)
Lung (adeno) 8.3 68* FP Outside None Curative operation 1.5 (alive)
Bile duct 8.7 40 FP Outside Jaundice Palliative chemo 0.79 (died of SPC)
Lung (small) 9.5 75 FP Outside None Chemo 1.1 (alive)
Adeno¼adenocarcinoma; chemo¼chemotherapy; DP¼docetaxel and cisplatin; FP¼5-fluorouracil and cisplatin; RT¼radiation; small¼small-cell carcinoma; SPC¼second
primary cancer; *The number of 68 was the value at the time of diagnosis of initial NSCLC and this patient had continued smoking as SPC was found.
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useful to identify early stage lung cancer, however, additional
examinations such as ultrasonic abdominal imaging, occult blood
stool tests, endoscopy, or measurement of tumour markers may
also be beneficial for early detection of alimentary canal cancer
in such patients with high-risk of SPC. Further investigation of
follow-up methods including cost-benefit analysis is necessary.
The studies using the person-years method to calculate the
incidences of SPC showed a range from 1.7 to 4.3 per 100 patient-
years (Thomas and Rubinstein, 1993; Ginsberg and Rubinstein,
1995; Martini et al, 1995; Jeremic et al, 2001; Kawaguchi et al,
2006). In the present studies, the rate of SPC was 2.4 per 100
patient-years, in agreement with previous findings. Chemotherapy
and RT may be carcinogenic treatments and may have contributed
to SPC compared with surgery for early NSCLC (Allan and Travis,
2005). Patients with locally advanced NSCLC still have poor
prognosis. Concurrent platin-containing CRT prolongs survival
(Aupe ´rin et al, 2006), despite the increased risk of SPC in long-
term survivors. In this study, it is difficult to speculate on the
association of SPC with RT because only one SPC was present in
the RT field.
Despite the small sample size in these studies, a significant
number of patients treated with concurrent CRT for locally
advanced unresectable stage IIIA and IIIB NSCLC survived more
than 5 years. Brain metastases in long-term NSCLC survivors have
been widely reported and have been the focus of several studies
(Carolan et al, 2005; Gaspar et al, 2005). As we observed that SPC
occurs just as frequently, long-term survivors require vigilant
follow-up to detect SPC at the earliest possible stage. Studies to
find methods to prevent SPC in such patients are warranted.
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Figure 2 Cumulative incidence of SPC from the initiation of concurrent
CRT.
2nd malignancy after chemoradiation for NSCLC
N Takigawa et al
1144
British Journal of Cancer (2006) 95(9), 1142–1144 & 2006 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
s